Aldehyde dehydrogenase 1 A1 (ALDH1A1) has recently been suggested as a marker for cancer stem or stem-like cancer cells of some human malignancies. The purpose of this study was to investigate the stem cell-related function and clinical significance of the ALDH1A1 in bladder urothelial cell carcinoma. pathologic characteristics and heterogeneity of the parental cells. High ALDH1A1 expression was found in 26% (56 of 216) of human bladder tumor specimens and significantly related to advanced pathologic stage, high histologic grade, recurrence and progression, and metastasis of bladder urothelial cell carcinomas (all P < 0.05). Furthermore, ALDH1A1 expression was inversely associated with cancer-specific and overall survivals of the patients (P = 0.027 and 0.030, respectively). Therefore, ALDH1A1
Introduction
There are ∼336,000 new cases of urothelial bladder carcinoma and 132,000 deaths annually all throughout the world (1) . Sixty percent of bladder carcinomas are lowgrade (G1, G2) and noninvasive cancers (Ta and T1/ pTis). Twenty-five percent newly diagnosed bladder tumors are high-grade (G3)/muscle invasive lesions (greater than pT2; ref. 1). The patients with low grade and nonmuscle-invasive carcinomas are routinely treated by endoscopic resection. After endoscopic resection, the majority of the patients develop cancer recurrences. The patients with high histologic grade and muscle-invasive tumors receive more aggressive therapies including cystectomy and/or radiation/chemotherapy; at least half of the cases eventually progress with local and distant metastases. Periodic cystoscopy and urine cytology are currently used to monitor the patients for cancer recurrence or progression (2) . However, these clinical means are associated with high cost, substantial patient discomfort, and variable and poor accuracy. Therefore, novel and clinically applicable prognostic markers are urgently needed to identify patients at high risk for poor prognosis. To date, numerous potential markers have been identified by a variety of molecular biology and genetic studies (3, 4) . However, the role of these molecular markers in clinical diagnosis and therapeutic decision making still remains uncertain. New diagnostic modalities have to be developed.
Accumulating evidence has proposed that tumor contains tumor-initiating cells or cancer stem cells (CSC) that are responsible for its progression and relapse (5) . Although being present in a small population in tumor, CSCs can undergo self-renewal, recapitulate the phenotype of the cancer from which they were derived, proliferate, and drive continued expansion of malignant cells (5) . Bladder carcinoma growth and metastasis might also be promoted by CSCs that are responsible for its aggressiveness (6) (7) (8) (9) (10) . Therefore, analysis of molecular aberrations that are associated with CSCs would deepen our understanding of the tumor biology of urothelial carcinoma. Most importantly, these molecular changes could be developed as a new diagnostic system for monitoring the progression of bladder tumor and offer the best opportunity to prevent its recurrence, and probably cure the challenging malignancy (9, 10) .
Human cytosolic aldehyde dehydrogenase 1 (ALDH1) plays a role in the biosynthesis of retinoic acid (11) . Altered metabolism of retinal to retinoic acid is likely to play a major role in stem cell biology (12) (13) (14) (15) (16) (17) (18) (19) . ALD-H1A1 is a major member of the ALDH1 family. Activation of ALDH1A1 has been found in stem cells populations in multiple myeloma and acute myeloid leukemia (19, 20) . Ginestier et al. (21) showed that ALD-H1A1 was a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome of breast cancer patients. We recently showed that the ALDH1A1 + lung cancer cells could generate tumors that recapitulated the heterogeneity of lung carcinomas (22) . Furthermore, elevated ALDH1A1 expression was correlated with the stage and grade of lung tumors and associated to a poor prognosis for the patients (22) . However, no research has been reported about the role of ALDH1A1 in tumorigenesis of bladder urothelial cell carcinoma and its clinical importance in the challenge malignancy.
To investigate the CSC-related function and clinical significance of ALDH1A1 in bladder urothelial cell carcinoma, we first isolated ALDH1A1 + cells from human bladder cancer cells by using Aldefluor assay and fluorescence-activated cell sorting (FACS). The ALDH1A1 + cells exhibited high in vitro tumorigenicity and initiated xenografts that gave rise to heterogeneous cell populations. Furthermore, immunohistochemistry (IHC) analysis of clinical specimens showed that ALDH1A1 expression correlated significantly with poor patient prognosis. ALDH1A1 might therefore be a bladder CSC-associated marker and might provide a potential prognostic factor for the malignant progression of bladder cancer.
Patients and Methods

Cell Lines and Cultures
Bladder cancer cell lines HTB-2, HTB-9, and HTB-4 were obtained from the American Type Culture Collection. The cells were maintained in the culture medium recommended by the American Type Culture Collection and were harvested by using treatment with 0.25% trypsin (Invitrogen) when they were in the logarithmic phase of growth for use in the following experiments.
Isolation of ALDH1A1
+ Cell Population by Aldefluor Assay and FACS An Aldefluor kit (StemCell Technologies) optimized for interaction with human ALDH1A1 was used to identify ALDH1A1 + cells as described in our previous study (22) . Briefly, the brightly fluorescent ALDH1A1-expressing cells were detected by using an Aria cell sorter (BD Biosciences). Side-scatter and forward-scatter profiles were used to reduce cell doublets. Nonviable cells were eliminated using the viability dye 4′,6-diamidino-2-phenylindole (Sigma). Specific ALDH1A1 activity was based on the difference between the presence/absence of the Aldefluor inhibitor diethylaminobenzaldehyde (Sigma).
FACS of CD44
+ and CD44 − Cell Population Cells were stained for 15 min at 41°C in TBS containing bovine serum albumin and FITC-conjugated monoclonal anti-CD44 (BD Pharmingen) and were then used to sort out CD44 + and CD44 − cells as previously described (23) . For the positive population, only the top 10% most brightly stained cells were selected. For the negative population, only the bottom 5% most dimly stained cells were chosen. Data were analyzed by using the CellQuest software (BD Biosciences). Each experiment was repeated thrice.
Immunofluorescence Analysis
ALDH1A1 and CD44 expressions in the bladder cancer cells were analyzed by using immunofluorescence assay with the primary antibodies against ALDH1A1 (Santa Cruz Biotechnology) and CD44 (eBioscience) as previously described (22, 23) . The cells were then stained with a fluorescently conjugated IgG (Abcam, Inc.) and were examined under a Leica microscope (Leica Microsystems, Inc.). Each batch of slides contained a positive control and a negative control.
Clonal Analysis and Clonogenic Assays
To evaluate differences in cell survival and proliferation between ALDH1A1 + and ALDH1A1 − cells. Cells were plated at density of 200 per well in a six-well tissue culture dish as described in our previous report (22) . Clones with >50 cells were scored at the end of week 2. The percentage of cells that initiated a clone was presented as cloning efficiency. For clonogenic assays, cells were plated at 1,000 per well in six-well culture dishes coated with a thin layer of 1% solidified agar (22) . Spheres that arose within 3 wk were considered as clonogenicity. For each cell type, triplicate samples were done and the clones or spheres were counted by two individuals in a blind fashion.
Effects of ALDH1A1 Knockdown on Tumorigenicity/ Clonal Growth
We made a small interfering RNA (siRNA) plasmid construct to specifically knock down ALDH1A1 according to a protocol described by Moreb et al. (24) . PSilencer 2.0-U6 siRNA plasmids (Ambion) were used to produce ALDH1A1 LV siRNA vectors. The target site for ALD-H1A1 (Genbank NM_000689) was 5′-gtagccttcacaggatcaa-3′ (nt 777-795). Primers used to generate the siRNA construct were 5′-ATA CGC GGA TCC CGT AGC CTT CAC AGG ATC AAT TCA AGA G AT TGA TC-3′ and 5-′CGC TAG ACT AGT TAA AAA AGT AGC CTT CAC AGG ATC AAT CTC TTG AA TTG ATC-3′. U6 promoter-driven LV-scrambled siRNA was also generated as previously described (25) and used as a control.
The plasmids were transfected into the 293T cells to produce lentiviral vectors using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. The lentiviral siRNA specific against ALDH1A1 was referred as lentiviral-ALDH1A1-siRNA. The sorted ALDH1A1 + cancer cells were transfected with lentiviral-ALDH1A1-siRNA and controls as previously described (24) . The effects of ALDH1A1 knockdown on tumorigenicity/clonal growth of these bladder cancer cells were investigated using the above assays.
− , and unsorted cancer cells were s.c. inoculated in 10 athymic Swiss nu/nu mice per each cell type at different dose ( Table 1 ). The mice were observed to allow tumor growth and then euthanized under deep anesthesia with pentobarbital (Sigma) at the end of week 4. The tumors were surgically removed, and their volume (mm 3 ) was calculated as (W 2 × L)/2. A portion of each tumor tissue was fixed in 10% formaldehyde and was embedded in paraffin for histopathologic examination. Additionally, a part of each engrafted tumor was dissociated with collagenase IV (Sigma) and incubated with mechanical disruption as previously described (22) . Serial transplantations of the bladder cancer xenografts were done by regrafting the freshly disassociated cells into mice. The disaggregated cells of xenograft tumors from each passage were also reanalyzed by using Aldefluor assay for the percentage of ALDH1A1 + cells as described above. 
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Cancer Epidemiol Biomarkers Prev; 19(2) February 2010 www.aacrjournals.orgadjuvant chemotherapy or radiation therapy before surgery. All patients with noninvasive bladder carcinomas (Ta-T1) were treated with intravesical chemotherapy after transurethral resection, whereas all patients with invasive disease (T2-T4) were treated with chemotherapy or radiotherapy after cystectomy. The median follow-up time was 98 (1-182) mo. Ninety-two of 216 patients were dead in the follow-up period. Among the 92 patients who died, 65 died of bladder cancer and the remaining 27 died of other causes without evidence of tumor progression. During the follow-up period, tumor recurrences and progression were observed in 140 and 69 patients, respectively. Furthermore, 22 normal urothelium specimens were obtained by biopsy or from cystectomized bladders for other diseases than cancer, which were used as normal controls. Tissue sections (4-mm thick) were obtained from each block, stained with H&E, and reviewed independently by two pathologists to confirm the diagnosis and the presence of tumor. The WHO 1973 criteria for grade and American Joint Cancer Committee 2002 tumor-node-metastasis classification were used to evaluate patients' histopathologic features.
IHC studies were done using a protocol as previously described (22, 23, 26, 27) . Briefly, after being deparaffinized in xylene and retrieved by boiling in a steamer with sodium citrate buffer, tissue sections were incubated with 10% normal horse serum/TBS for 30 min at room temperature. Antibodies against ALDH1A1 (Santa Cruz Biotechnology) and CD44 (eBioscience) were mounted for 1 h at room temperature. Respective secondary antibodies from the EnVision system (DAKO Carpinteria) were applied on the slides for 30 min. The slides were then rinsed in the 1 × TBS, visualized by a 5-min incubation with liquid 3,3′-diaminobenzidine in buffered substrate (DAKO), and counterstained with H&E (DAKO). Immunoreactive staining intensity for each antibody was rated according to the following scale: no visible staining, 0; faint staining, 1; moderate staining, 2; and strong staining, 3. The total number of cells with positive staining for the antibodies was quantized in 20 fields on each tissue section. Percentage of cells with positive staining was graded as 0%, <10%, 10% to 25%, 25% to 50%, and 50% to 75% or higher. An overall score was assigned by multiplying the intensity score by the mean percentage of cells staining.
Statistical Analyses
The clinical parameters of the patients, including tumor recurrence and progression, cancer-specific survival, and overall survival, were determined as previously described (27) . Data on various treatments including transurethral resection, cystectomy, intravesical Bacillus Calmette-Guérin (BCG) treatment, radiation, and chemotherapy were also collected during the time of each follow-up category. The patients' age, gender, grade, stage, tumor size, multiplicity, recurrence, progression, and various treatment modalities were collected as baseline variables. The χ 2 test was applied to evaluate the association between ALDH1A1 expression and the clinicopathologic parameters. The χ 2 test was also used for comparison of ordinal variables. Cancer-specific and overall survival rates were estimated by Kaplan-Meier method and were evaluated with the use of log-rank test for univariate analysis. Univariate and multivariate survival analyses were done using the Cox proportional hazards regression model. Statistical significance was set as P ≤ 0.05. All reported P values were two-sided.
Results
Identification of a Small ALDH1A1 + Subpopulation in Bladder Cancer Cell Lines with Increased Properties of Clonogenicity
The three different cell lines displayed a small and similar size of ALDH1A1 + population: HTB-2 showed 6.4% (6.4 ± 1.1%), HTB-9 had 8.2% (8.2 ± 2.0%), and HTB-4 exhibited 7.9% (7.6 ± 1.9%) ALDH1A1 + cells, respectively (Fig. 1A) . The percentage of CD44 + population in HTB-2, HTB-9, and HTB-4 cells was 69.4% (68.8 ± 5.3%), 72.1% (73.5 ± 6.3%), and 57.9% (57.3 ± 6.7%). Therefore, the ALDH1A1 + cell proportion (6.4-8.2%) in the bladder cancer cells was considerably lower than that of (57-72%) of CD44 + cells (P < 0.01; Fig. 1B ). To evaluate proportion of cell population positive for both ALDH1A1 and CD44 in the three cell lines, we first enriched CD44 + cells by using FACS with CD44 antibody, from which we then isolated ALDH1A1 + cells by using Aldefluor assay. CD44 + HTB-2 (16.5%; 16.8 ± 2.3%), HTB-8 (14.8%; 13.1 ± 3.1%), and HTB-4 (12.6%; 12.8 ± 2.9%) cells were also positive for ALDH1A1, respectively. Vice versa, after being serially enriched by Aldefluor assay followed by FACS with CD44 antibody, 79.2% (79.1 ± 4.8%), 82.6% (82.3 ± 5.2%), and 77.2% (77.3 ± 5.6%) of ALDH1A1 + HTB-2, HTB-8, and HTB-4 cells were positive for CD44. The results indicate that the ALDH1A1 + population might be a subset of the CD44 + cells. The observation was also confirmed by merged immunofluorescence imaging that showed that an average of 86.2% (86.6 ± 5.1%) ALDH1A1 + HTB-2 cancer cells were positive for CD44 staining (Fig. 1C) .
The ALDH1A1 + HTB-2, HTB-9, and HTB-4 cells displayed significantly higher colony-forming efficiency by forming larger and more clones (P < 0.0001) compared − bladder cancer cells to produce colonies by using soft agar assay. As shown in Fig. 2A − and unsorted bladder cancer cells to form colonies in the soft agar assay (P > 0.05). The results implied that ALD-H1A1 + cells had high clonogeniety and further enriching cancer cells using CD44 + could not increase clonogenic formation efficiency. Anchorage-independent growth in the soft agar assay has been suggested as an approximation of tumorigenesis, and CSCs are thought to be the tumor-initiating cells (28, 29) . Therefore, these in vitro observations indicate that ALDH1A1 + bladder cancer cells present higher survival, proliferation, and tumorigenicity compared with the isogenic ALDH1A1 − and CD44 + cells.
ALDH1A1 Knockdown on Tumorigenicity/Clonal Growth
The ALDH1A1 + HTB-2 cells transfected with lentiviral-ALDH1A1-siRNA showed reduced ALDH1A1 at least 75%. Furthermore, this downregulation was specific because there was no significant change of ALDH1A1 in the mock cells and the cells infected with the scrambled siRNAs (control cells). There was also no change in the expression of the other members of ALDH family in the cells treated with lentiviral-ALD-H1A1-siRNA.
The ALDH1A1 + HTB-2 cells, after their ALDH1A1 was reduced, exhibited considerably lower colony-forming efficiency by forming smaller and less clones than did the ALDH1A1 + HTB-2 cells whose ALDH1A1 was not knocked down (P < 0.0001). Furthermore, soft agar assay showed that the ALDH1A1 + HTB-2 cells, after the ALD-H1A1 was reduced, generated much less colonies compared with the enriched ALDH1A1 + HTB-2 cells without reduced ALDH1A1 expression (P < 0.0001). This observation implied that the increased tumorigenicity of ALDH1A1 cells was attributed to the expression of this molecule, altogether the data show that high ALDH1A1 expression could directly contribute to tumorigenicity in bladder cancer cells. ) in only one of the mice (Fig. 2B) We repeated the experiments using HTB-9 and HTB-4 bladder cancer cells and obtained similar results. These data, taken together with above in vitro findings, suggest that ALDH1A1 + cancer cells had higher tumorigenic potential compared with ALDH1A1 − , CD44 + , and unsorted populations.
Histopathologic examination revealed a highly cellular mass with the characteristics of bladder transitional cell carcinoma in the engrafts from the ALDH1A1 + bladder cancer cells (Fig. 2C) . Because the gold standard in determining CSCs is whether the testing cells can preferentially initiate tumor development in animal models (28, 29) , the observation could provide functional evidence that the ALDH1A1 + cancer cells have the property of in vivo self-renewal.
Furthermore, serial transplantation experiments showed that bladder tumors developed from ALDH1A1 + cells could be regenerated for three cycles until we prepared the article. To elucidate whether ALDH1A1 + cancer cells could create bladder tumors with heterogeneity in vivo, Aldefluor analysis was done on disassociated cells of the engrafts. The xenograft tumors in the first passage xenografts gave rise to 56.9% (58.7 ± 4.6%) ALDH1A1 + cells and 29.7% (29.3 ± 1.9%) ALDH1A1
− cells (Fig. 2D) . The percentage of the ALDH1A1 + and ALDH1A1 − population in the third passage xenografts were 44.9% (45.1 ± 3.2%) and 45.4% (46.2 ± 2.3%), respectively. The result again supports that the ALDH1A1 + cancer cells have the property of self-renewal in an animal model. Furthermore, it also indicates that ALDH1A1 + cancer cells could differentiate into ALDH1A1 − cells and thus create bladder tumors with heterogeneity in vivo.
ALDH1A1 Expression in Human Bladder Tissue Specimens
ALDH1A1 was not observed in the normal bladder specimens; however, it was found in bladder tumor tissues as illustrated by strong cytoplasm staining (Fig. 3A) . Furthermore, IHC analysis of serial tumor sections displayed that ALDH1A1 + cells existed within and were restricted to tumor cells that had positive CD44 staining (Fig. 3B) . The ALDH1A1 + cancer cells, therefore, accounted for a fraction of the CD44 + tumor cell population. The observation is consistent with the finding in the above in vitro experiments, in which, the ALDH1A1 + population is a subset of the CD44 + bladder cancer cells. To assess the clinical significance of ALDH1A1 expression in bladder cancer patients, we used a cutoff value to determine whether a tumor had low or high ALDH1A1 expression as previously described (22) , which was a tumor specimen with >10% overall score was defined as one with high ALDH1A1 expression. High expression of ALDH1A1 was found to be present in 26% (56 of 216) of the total bladder tumor samples. There was a stepwise increase in the prevalence of ALDH1A1 expression with the grades and stages of the bladder carcinomas (Table 2) : 14% (12 of 84), 23% (19 of 82), and 50% (25 of 50) in grade 1, 2, and 3, respectively (P = 0.01). Elevated ALDH1A1 expression was observed in 21% (33 of 160) of noninvasive urothelial carcinomas (12% Ta and 31% T1/pTis), 41% (24 of 46) advanced bladder carcinomas (T2-4), and 68% (13 of 19) lymph node metastases (P = 0.02). However, there was no significant association between ALDH1A1 expression and other clinicopathologic features such as patient's age and gender and tumor size, and multiplicity (Table 2) . Therefore, ALDH1A1 expression status was closely correlated with important histopathologic characteristics (grades and stages) of bladder urothelial carcinomas.
High ALDH1A1 Expression Was Related to Recurrence and Progression of Bladder Urothelial Carcinomas and Poor Prognosis of the Patients
In the follow-up period, 32% (45 of 140) of tumors with high ALDH1A1 expression recurred compared with 15% + tumor cell population. The immunohistochemical study of adjacent sections of a bladder tumor for the expression of ALDH1A1 and CD44 showed that a few ALDH1A1 + cells (arrows in A) were present within the CD44-immunopositive tumor areas (B). C, survival analysis of 216 patients with bladder urothelial carcinomas based on high ALDH1A1 expression status. C, cancer-specific survival time; D, overall survival time. P values were calculated using the log-rank test.
(11 of 76) of tumors with low ALDH1A1 expression having recurrence (P = 0.007; Table 2 ). Furthermore, 55% (38 of 69) of tumors with high ALDH1A1 expression showed progression, compared with only 12% (18 of 147) of tumors with low ALDH1A1 expression having progression (P = 0.001). Therefore, overexpression of ALDH1A1 was positively associated with the incidence of recurrence and progression of bladder urothelial carcinomas.
Kaplan-Meier plots and log-rank tests showed that the bladder cancer patients with high ALDH1A1 expression in their tumor tissues had statistically significant shorter cancer-specific survival, compared with those whose tumors had low ALDH1A1 expression (P = 0.027; Fig. 3C ). Moreover, patients with high ALDH1A1-positive staining in their tumors had statistically significantly shorter overall survival rate compared with those whose tumors had low ALDH1A1 expression (P = 0.030; Fig. 3D ). Therefore, ALDH1A1 expression in bladder urothelial carcinomas was inversely associated with poor prognosis of the patients.
Multivariate Cox proportional hazards regression analysis revealed that elevated ALDH1A1 expression in urothelial tumors was an independent predictor for cancer-specific and overall survival rates. Furthermore, tumor stage was associated with cancer-specific and overall survival rates (P = 0.002 and P = 0.027, respectively). Lymph node metastasis was also related with cancerspecific and overall survival rates of the patients (P = 0.013 and 0.029, respectively). In addition, treatments including Bacillus Calmette-Guérin, radiation therapy, and systematic chemotherapy could serve as significant factors for cancer-specific survival (all P < 0.05), whereas age was only shown to be an independent prognostic factor for overall survival of bladder cancer patients (P = 0.039).
Discussion
The development of specific markers to isolate and characterize CSCs or stem-like cancer cells of urothelial bladder carcinoma would greatly advance our understanding of the tumor biology of bladder. In this study, we first isolated ALDH1A1 + cells from bladder cancer cell lines by uisng Aldefluor assay and then evaluated their CSC-associated function by in vitro and in vivo approaches. Important properties of CSCs include in vitro self-renewal, in vivo tumor initiation, and giving rise to a heterogeneous population of cancer cells. The observation of a minority (26%) of cancer samples positive for ALDH1A1 was consistent with the findings in other types of human solid malignancies (21, 28, 32) . For example, increased ALDH1A1 expression occurred in 30% of 345 breast tumor specimens (21) . We recently found that elevated ALDH1A1 expression existed in 29% human lung tumor tissues (22) . Especially, our current observation agrees with the feature of CSCs that only account for small population of cancer cells within tumors (5, 30) . Therefore, the data further provides evidence supporting that the ALDH1A1 + cancer cells might be enriched in tumor-stem cells or CSCs of bladder urothelial cell carcinoma.
The development of molecular biomarkers that can predict bladder cancer cells to recur and progress would help identify tumors that could benefit the most effective treatments, and is thus clinically important. We showed that increased ALDH1A1 expression levels were correlated with advanced tumor grade and stage. Furthermore, patients with elevated ALDH1A1 expression in their tumors had higher recurrence and shorter survival rates compared with patients with low ALDH1A1 expression. In addition, the increased ALDH1A1 expression was an independent prognostic factor for both cancer-specific and overall survivals in the patients. The findings are potentially important in practice because the IHC staining for detecting ALDH1A1 changes is a simple and readily available assay, and will easily be performable in clinical settings. Moreover, the ALDH1A1 antibody specifically binds its target with very low or no background, reducing inconsistent or variable results of IHC. The future application of an automated instrument with standard protocol will diminish interobserver and intraobserver variations in the interpretation of IHC staining results (33) . Therefore, ALDH1A1 would potentially be added to the current prognostic methods to improve the accuracy of clinical outcome predictions and the choice of appropriate therapy for bladder cancer patients who might have disease recurrence and progression.
The ALDH1A1 gene is ∼53-kb long and contains 13 exons, encoding a 501-residue protein (16) . Human ALDH1 isozyme is expressed at different levels in various tissues, with the highest level in the liver and the lowest or undetectable levels in the heart (17), implying the ALDH1 expression is tissue specific. The molecular mechanism of its tissues-specific expression has been investigated (11, 17, 18) . Yanagawa et al. (11) found that the 5′-flanking region of ALDH1A1 contains several putative regulatory elements. These include NF-IL6, HNF-5, GATA binding sites, and putative response elements for interleukin-6, phenobarbital and androgen, a noncanonical TATA box (ATAAA), and a CCAAT box. The protein level in various types of human cells might be regulated at the transcriptional level (11, 18) . For example, they defined a minimal promoter region from −91 to −53 bp of human "liver" ALDH1 and observed a 65-fold increase in chloramphenicol acetyltransferase activity in a hepatoma cell line, Hep3B. In contrast, only 6-to 7-fold increases in chloramphenicol acetyltransferase activity were found in a human leukemia cell line, K562. Whether and how ALDH1A1 is regulated at the transcriptional level in human urinary bladder urothelial cells is currently investigated at our laboratory. The study would deepen our understanding of the ALDH1A1 function in the malignant transformation of stem cells in carcinogenesis of bladder.
In summary, we show that ALDH1A1 + bladder cancer cells are endowed with extensive tumorigenicity and selfrenewal potential, being able to generate tumors that resemble the histopathologic characteristics and heterogeneity of the parental tumor cells, and thus have the properties of CSCs or stem-like cancer cells. Furthermore, ALDH1A1 could function as a prognostic factor for predicting outcome in patients with the challenge malignancy. Nevertheless, a longitudinal clinical study in a large population to validate its prognostic value for improving treatment efficiencies of bladder cancer will be needed.
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